A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

Phase 2 Completed 248 enrolled Hanmi Pharmaceutical Company Limited

RandomizedParallel-groupDouble-blindTreatment

Summary

A multicenter, randomized, double-blind, parallel, phase 2 study to assess dose-response relationship of HCP1803 in patients with essential hypertension

Timeline

Start: 2019-03-21
Primary completion: 2020-02-26
Completion: 2020-02-26

Publications

Hong SJ, Sung KC, Lim SW, Kim SY, Kim W, Shin J, Park S, Kim HY, Rhee MY; HM_APOLLO Investigators. Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study. Drug Des Devel Ther. 2020 Dec 31;14:5735-5746. doi: 10.2147/DDDT.S286586. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Amlodipine	Other / unclassified	5 mg	—
Comparator	Amlodipine	Other / unclassified	10 mg	—
Subject	HCP1803	Unknown	—	—
Comparator	Losartan	Other / unclassified	100 mg	—

A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

Summary

Timeline

Publications

Drugs

Indications